ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Isovanillic acid alleviates dextran sulfate sodium-induced ulcerative colitis in mice by improving mitochondrial function
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the protective effect of isovanillic acid (IVA) against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice and its underlying mechanism.
methodsForty-eight male C57BL/6 mice were randomly divided into 6 groups (
resultsThe DSS-treated mice showed significantly decreased body weight, increased DAI score, shortened colon length, elevated colonic IL-6 and IL-1β expressions, and severe mucosal damage. IVA, especially at the medium and high doses, obviously improved these changes. Treatment with medium-dose IVA-M significantly increased colonic expressions of ZO-1 and claudin-1, decreased intestinal epithelial cell apoptosis rate and expressions of Bax and cleaved caspase-3, and increased Bcl-2 expression, TOMM20-positive cell counts, and activities of mitochondrial respiratory chain complexes I and IV. In NCM460 cells, IVA treatment obviously reversed DSS-induced mitochondrial impairment, reduced epithelial cell apoptosis, and enhanced expressions of ZO-1 and claudin-1. Network pharmacology analysis suggested that IVA potentially targeted the PPARγ pathway, which was confirmed by increased PPARγ protein expression in IVA-treated mice and NCM460 cells. Treatment with the PPARγ antagonist GW9662 significantly attenuated the protective effect of IVA in DSS-induced NCM460 cells.
conclusionsIVA alleviates DSS-induced colitis in mice by protecting mitochondrial function via activating the PPARγ pathway and suppressing inflammation and apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.